Frontotemporal disorders (FTD) encompass a group of neurodegenerative conditions affecting the frontal and temporal lobes of the brain, leading to progressive cognitive and behavioral decline. As ...

Westport makes the world’s entire supply of the anti-wrinkle drug — now the feat is that production could move to the US ...

The market is characterized by trends such as personalized medicine, targeted therapies, and combination treatments. Key players include Eli Lilly, B ...

Verve Therapeutics saw its stock surge by more than 26% when markets opened today (14 April) after the company announced early-stage clinical data for its Eli ... from Lilly is expected in H2 2025.

Donald Trump again has raised the prospect of a new tariff on imported pharmaceuticals, reportedly pitched at a 25% rate.

The global dermatology drugs market, valued at approximately US$ 19.71 billion in 2023, is on track to experience robust growth, with projections estimating it will reach US$ 50.4 ...

Goldman Sachs analyst Asad Haider upgraded Eli Lilly (LLY) to Buy from Neutral, while decreasing its price target to $888 from $892 per share. The brokerage firm upgraded Johnson & Johnson (JNJ ...

Elanco, the animal health division of Eli Lilly and Company, today announced the company will purchase the Titanium and Master Guard brands from AgriLabs. These well-known cattle vaccine brands will ...

Eli Lilly and Company traded as low as $718.81 and last traded at $718.89. Approximately 663,002 shares changed hands during trading, a decline of 80% from the average daily volume of 3,354,701 ...

On the heels of similar investment pledges from Eli Lilly and Johnson & Johnson, Switzerland’s Novartis is stepping up to the plate with a major plan to grow its U.S. footprint. Novartis will ...

Drugmakers have said they’re still unclear about whether Trump will impose tariffs on finished products or on active pharmaceutical ingredients.

One of them is the pharmaceutical industry. However, some major executives in the sector are not optimistic, including Eli Lilly's (NYSE: LLY) CEO, David Ricks. Start Your Mornings Smarter!